Incyte Corp
NASDAQ:INCY

Watchlist Manager
Incyte Corp Logo
Incyte Corp
NASDAQ:INCY
Watchlist
Price: 74.8 USD 1.74% Market Closed
Market Cap: 14.4B USD
Have any thoughts about
Incyte Corp?
Write Note

Incyte Corp
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Incyte Corp
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
Incyte Corp
NASDAQ:INCY
Effect of Foreign Exchange Rates
-$7.8m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Effect of Foreign Exchange Rates
$4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Effect of Foreign Exchange Rates
$52m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Effect of Foreign Exchange Rates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Effect of Foreign Exchange Rates
$32.1m
CAGR 3-Years
51%
CAGR 5-Years
N/A
CAGR 10-Years
35%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Effect of Foreign Exchange Rates
$200k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Incyte Corp
Glance View

Market Cap
14.4B USD
Industry
Biotechnology

Incyte Corporation, a biopharmaceutical company founded in 1991, has carved out a significant niche in the oncology and hematology sectors by focusing on the development and commercialization of innovative therapies. With a robust pipeline that includes targeted drugs and novel approaches to cancer treatment, Incyte has established its reputation as a leader in addressing challenging diseases. The company's flagship product, Jakafi, was the first FDA-approved therapy for myelofibrosis—a rare type of bone marrow cancer—and has since opened new avenues for treating various blood disorders. Investors will appreciate Incyte's strategic collaborations, like its partnership with Eli Lilly for the development of various compounds, which not only bolster its research pipeline but also diversify its revenue streams. As the company continues to expand its footprint in the biopharmaceutical landscape, Incyte is actively pursuing new indications for Jakafi and furthering its research into other key candidates. The firm is driven by a mission to transform cancer treatment, underpinned by strong clinical trial data and a commitment to innovation. Given the growing demand for effective cancer therapies, coupled with Incyte’s solid financial footing and ability to navigate the competitive landscape, the company presents an appealing opportunity for investors seeking exposure to the biotech sector. With a clear vision and a focus on unmet medical needs, Incyte stands poised to deliver sustained growth and long-term value in an evolving industry.

INCY Intrinsic Value
89.19 USD
Undervaluation 16%
Intrinsic Value
Price

See Also

What is Incyte Corp's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
-7.8m USD

Based on the financial report for Sep 30, 2024, Incyte Corp's Effect of Foreign Exchange Rates amounts to -7.8m USD.

What is Incyte Corp's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 3Y
-10%

The average annual Effect of Foreign Exchange Rates growth rates for Incyte Corp have been -10% over the past three years .

Back to Top